Tramadol (Ultram)

• Core Use: Atypical opioid for moderate pain; weak μ-opioid agonist with serotonin/norepinephrine reuptake inhibition (SNRI-like effects); Schedule IV controlled substance
• Standard Adult Dose: IR: 25–50 mg PO q6h PRN (start lower in elderly/frail); max 400 mg/day (or 300 mg/day in older adults)
• Onset/Duration: Oral onset slower than IV opioids (peak ~2 hours for IR); not ideal for rapid titration in severe acute pain
• Key Dangers: Seizure risk (even at therapeutic doses), serotonin syndrome when combined with SSRIs/SNRIs/MAOIs, variable response due to CYP2D6 polymorphisms, typical opioid risks (respiratory depression, dependence)
• Special Note: CONTRAINDICATED in children <12 years and <18 years post-tonsillectomy/adenoidectomy due to risk of fatal respiratory depression; many guidelines now advise caution in elderly and those on serotonergic medications

• Generic Name: Tramadol hydrochloride
• Brand Names: Ultram, Ultram ER, ConZip, various generics
• Regulatory Status: Schedule IV controlled substance (U.S.) - abuse and dependence potential

Atypical centrally acting analgesic; weak μ-opioid receptor agonist and serotonin/norepinephrine reuptake inhibitor (SNRI-like)

Mechanism of Action:

• Parent drug: weak μ-opioid receptor agonist with relatively low affinity compared with traditional opioids
• Active metabolite (O-desmethyltramadol, M1) formed by CYP2D6 has significantly higher μ-opioid potency and contributes heavily to analgesic effect
• Also inhibits serotonin (5-HT) and norepinephrine reuptake in the CNS, similar to SNRI antidepressants, augmenting descending inhibitory pain pathways
• The serotonergic and noradrenergic actions are implicated in the risk of serotonin syndrome, seizures, and potential mood/behavioral effects
• Racemic mixture: (+)-enantiomer more serotonergic, (−)-enantiomer more noradrenergic; combined effects yield the overall analgesic and adverse-effect profile

Pharmacokinetics:

• Absorption: Oral tramadol is well absorbed with bioavailability ~70–75% after repeated doses; IR peak ~2 hours, ER peak ~4–6 hours
• Distribution: Volume of distribution ~2.6–2.9 L/kg; ~20% bound to plasma proteins
• Metabolism: Extensively hepatic via CYP2D6 (to active M1 metabolite) and CYP3A4/CYP2B6 to other metabolites
• Elimination: Renal excretion of parent and metabolites; elimination half-life ~6–7 hours for tramadol and ~7–9 hours for M1 metabolite in normal renal function
• Special Considerations: Renal impairment significantly prolongs elimination; both dose and dosing interval should be adjusted in CrCl <30 mL/min and in older adults
• Genetic Polymorphisms: CYP2D6 variability causes large inter-individual variability in analgesic response and toxicity (poor vs ultrarapid metabolizers)

• Short-term management of moderate pain when non-opioid options are insufficient and stronger opioids are undesirable (e.g., some musculoskeletal pain, mild post-op pain)
• Step-down analgesic when transitioning from IV or stronger oral opioids in selected patients with lower risk for seizures/serotonin toxicity
• Generally NOT preferred for: Severe acute pain, hemodynamically unstable patients, or those at significant risk for seizures or on multiple serotonergic agents

Available Forms:

• Immediate-release (IR) tablets/capsules: 50 mg; some products 37.5 mg in combination with acetaminophen (e.g., tramadol 37.5 mg / APAP 325 mg)
• Extended-release (ER) tablets/capsules: 100 mg, 150 mg, 200 mg, 300 mg (formulations vary)
• Oral solution (less common): concentration varies by manufacturer; used in special populations when tablets cannot be swallowed
• IV/IM tramadol exists in some countries but is not commonly used or available in the U.S.; ED/ICU practice here is primarily oral

Dosing – Tramadol (Adult PO; always follow local guidelines):

Contraindications:

• Hypersensitivity to tramadol or any component of the formulation
• Children <12 years; post-tonsillectomy/adenoidectomy patients <18 years (risk of fatal respiratory depression)
• Significant respiratory depression or acute/severe bronchial asthma in an unmonitored setting
• Concurrent or recent (within 14 days) MAOI use due to serotonin syndrome risk
• Uncontrolled epilepsy or significant seizure disorders (relative/strong contraindication)

Major Precautions:

• Concomitant use with serotonergic drugs (SSRIs, SNRIs, TCAs, MAOIs, linezolid, triptans) increases risk of serotonin syndrome (agitation, hyperreflexia, clonus, hyperthermia)
• Concomitant use with other CNS depressants (benzodiazepines, alcohol, other opioids, sedative-hypnotics) increases risk of profound sedation, respiratory depression, coma, and death
• History of seizures, head injury, CNS infection, or metabolic disorders that lower seizure threshold; tramadol can precipitate seizures even at therapeutic doses
• Elderly patients, those with renal/hepatic impairment, or COPD/OSA are at higher risk for adverse CNS and respiratory effects; use lower doses and close monitoring
• Risk of abuse, misuse, and dependence similar to other opioids, though somewhat lower potency; monitor for aberrant drug-related behaviors
• Avoid abrupt discontinuation after prolonged use to prevent opioid withdrawal; taper gradually if used chronically

Common:

• Nausea, vomiting, constipation, dry mouth
• Dizziness, somnolence, headache, fatigue
• Sweating, pruritus
• Mild confusion or cognitive slowing, especially in older adults

Serious:

• Seizures, even at recommended doses, especially with predisposing factors or interacting drugs
• Serotonin syndrome when combined with other serotonergic medications
• Life-threatening respiratory depression, particularly in CYP2D6 ultrarapid metabolizers, children, and when combined with CNS depressants
• Opioid use disorder, misuse, and overdose (Schedule IV controlled substance)
• Hypoglycemia (reported in some observational studies, particularly in older or renally impaired patients)
• Anaphylaxis or severe hypersensitivity reactions (rare)

Pediatric:

• CONTRAINDICATED in children <12 years
• CONTRAINDICATED in children/adolescents <18 years post-tonsillectomy and/or adenoidectomy
• Avoid use in any child with suspected obstructive sleep apnea, respiratory compromise, or concomitant CNS depressants

Elderly (≥65 years):

• Start with lower doses (25–50 mg q8–12h) and titrate cautiously
• Maximum 300 mg/day (lower than younger adults)
• Increased risk of confusion, dizziness, falls, and respiratory depression

Renal Impairment:

• CrCl <30 mL/min: Maximum 200 mg/day; extend dosing interval to q12h
• Avoid ER formulations in severe renal impairment

Hepatic Impairment:

• Moderate to severe: 50 mg q12h or less; ER formulations generally not recommended
• Increased risk of accumulation and toxicity

Pregnancy & Lactation:

• Avoid during pregnancy when possible; risk of neonatal opioid withdrawal syndrome with prolonged use
• Present in breast milk; avoid in breastfeeding due to risk of infant sedation and respiratory depression

Clinical Monitoring:

• Pain relief vs adverse effects (sedation, dizziness, nausea); reassess frequently, especially after dose changes
• Respiratory rate, oxygen saturation, and level of consciousness in patients at risk for respiratory depression or on concomitant CNS depressants
• Mental status and neuromuscular exam (clonus, hyperreflexia) when used with serotonergic drugs or if serotonin syndrome suspected
• Signs of seizure activity in high-risk patients or those on interacting medications (e.g., bupropion, TCAs, antipsychotics)

Long-Term Monitoring:

• Monitor for misuse/abuse, dependence, and the need for tapering rather than abrupt discontinuation
• Renal and hepatic function periodically in those with known impairment or on prolonged therapy

• 1. Lexicomp. (2024). Tramadol: Drug information. Wolters Kluwer.
• 2. Grond, S., & Sablotzki, A. (2004). Clinical pharmacology of tramadol. Clinical Pharmacokinetics, 43(13), 879–923.
• 3. FDA. (2017). Tramadol: Drug safety communication – strengthened warnings about use in children and breastfeeding women.
• 4. Hernandez, N., & Nelson, L. S. (2010). Tramadol: Seizures, serotonin syndrome, and co-ingestants. Journal of Medical Toxicology, 6(4), 345–352.
• 5. DrugBank Online. (2024). Tramadol. https://go.drugbank.com/